-
3 weeks ago | 
timmermanreport.com | David Shaywitz |Luke Timmerman
This week featured a rare crossing of the streams, as the buttoned-down world of cancer research met the buzzy world of exercise and wellness. One result: a randomized controlled study of exercise in 889 cancer patients published in the New England Journal of Medicine (NEJM), and accompanied by a torrent of enthusiastic coverage in the popular press. Another: the publication of two important and thoughtful commentaries about this study, analyses that are the focus of today’s column.
-
1 month ago | 
aei.org | Scott Gottlieb |James Pethokoukis |David Shaywitz |Benedic Ippolito
Press CNBC Discussing the impact of President Trump’s policies on life science investment and innovation: Gottlieb on CNBC’s ‘Squawk Box’ Article How to Stop the Shift of Drug Discovery from the US to China Press Discussing the new Trump Administration and US health policy: Gottlieb on CNBC’s ‘Special Report’ Press CNBC Discussing the GLP-1 Drug Trade and Developments: Gottlieb on CNBC’s “Fast Money” Article Will the Anti-Obesity Wonder Drugs Work Wonders for the US Economy? Press CNBC...
-
1 month ago | 
timmermanreport.com | David Shaywitz |Luke Timmerman
Consumer health and wellness is experiencing a flurry of activity. The lab testing company Function (motto: “It’s time to own your health”) acquired Ezra, a whole body MRI company promising “the world’s most advanced longevity scan.” Oura, maker of the popular smart ring, recently added an integration for continuous glucose measurement as well as the ability to calculate meal nutrition based on a photo.
-
1 month ago | 
aei.org | David Shaywitz |Brian Miller |Sally Satel |Timothy Carney
Op-Ed ‘Super Agers’ Review: Living the Good Life Op-Ed Our Collective Hope for AI in Health, Plus Explanatory Models and an Epic Podcast Article Restraining Health Spending While Protecting Access: Potential For Bipartisan Action Event Health Policy Under the New Administration Op-Ed “What Is It Like to Be an Addict?” Review: The Danger of a Safe Feeling Op-Ed Are the FDA and Drugmakers Covering Up the Abortion Pill’s Risks? Op-Ed Silicon Valley’s Consumer Eugenics Podcast Doctors Are Still...
-
1 month ago | 
timmermanreport.com | David Shaywitz |Luke Timmerman
For at least a decade, nearly every tech company has promoted their product as facilitating the “democratization” of something – perhaps “data driven medicine,” or “genetic information” or “access to clinical trials” or “digital health” (all real examples). Like “mission-driven,” “results-oriented,” and “disruptive,” the term “democratization” has become so overused by the tech community that it’s now more of an obligatory buzzword than a meaningful, resonant concept.
-
1 month ago | 
timmermanreport.com | David Shaywitz |Luke Timmerman
A recent piece by Nathan Price captures our collective hope for AI in health with unusual clarity, even as there remains impassioned disagreement regarding how close these ambitions are to meaningful realization. For context, Price is Professor and Co-Director of the Center for Human Healthspan at the Buck Institute for Research on Aging and CSO of Thorne, a company best known for its supplements, and which is now expanding into testing.
-
2 months ago | 
timmermanreport.com | David Shaywitz |Luke Timmerman
(Guest) Editor Note: Martin Gaynor, the Lester A. Hamburg University Professor of Economics and Public Policy at Carnegie Mellon University, was recently honored with the Victor R. Fuchs Award for Lifetime Contributions to the Field of Health Economics by the American Society of Health Economists. His response (shared with his permission) was both striking and magnificent, emphasizing the contingency of his career path, and acknowledging the many different ways things might have turned out.
-
2 months ago | 
timmermanreport.com | David Shaywitz |Luke Timmerman
Can you improve your health without obsessing about it? I’ve been, well, obsessing about this question as I continue to spend more time and mindshare in the world of healthy aging evangelists, enthusiasts, and entrepreneurs, longevity champions keen to guide you, and often test you, towards their conceptions of healthier aging. (See this piece on the longevity boom, and this on the role of GLP-1RAs.)Athletes and ConvertsThere seem to be two general flavors of longevity champions.
-
Mar 29, 2025 | 
timmermanreport.com | Enhancing Agency |David Shaywitz |Luke Timmerman
The arrival of generative AI prompted many to worry about the adverse impact on human agency; after all, if the technology can effectively do what we’re doing, where does that leave us? This concern was the central focus of Reid Hoffman’s “Superagency,” which I reviewed for the WSJ earlier this year – see here. Essentially, Hoffman argues that new technologies can take some time to adjust to, but ultimately they empower us to do more things and greater things.
-
Mar 28, 2025 | 
timmermanreport.com | Enhancing Agency |David Shaywitz |Luke Timmerman
Dying, with few exceptions, has never been especially popular, and our shared interest in not dying hardly constitutes breaking news. Nevertheless, the aspiration of living longer — and remaining healthier while doing it — appears to be all the rage. Consider these recent headlines:“Why is longevity sudden so hot?” – Chrissy Farr, Second Opinion. “The longevity business is booming – and its scientist are clashing” – Amy Dockser Marcus, The Wall Street Journal.
